Navigation Links
Cephalon Presents Positive Results for Fentora in Breakthrough Pain,,,Associated with Neuropathic Conditions

ned to provide early-onset analgesia via a chemical reaction that enhances fentanyl absorption across the inner lining of the cheek. Cephalon is pursuing clinical development of FENTORA in breakthrough pain associated with conditions other than cancer, including chronic neuropathic pain, and expects to file a supplemental New Drug Application this year. FENTORA is not approved for use in these conditions.

The multi-center study evaluated FENTORA in adult patients with chronic neuropathic pain who were diagnosed with a variety of conditions including diabetic peripheral neuropathy, traumatic injury, postherpetic neuralgia and complex regional pain syndrome (CRPS) -- a chronic condition caused by a nerve disorder that occurs at the site of injury, often a fractured arm or leg. All patients were already receiving various around-the-clock opioid medications for persistent pain, and short-acting opioids for their one to four episodes of breakthrough pain a day.

The open label titration phase of the study enrolled 103 patients who were individually titrated to a dose that provided adequate pain relief for at least two of three breakthrough pain flares. Of these, 102 patients received at least 1 dose of FENTORA and 80 patients (78 percent) identified a successful dose with acceptable side effects. Only six patients (6 percent) withdrew from the study due to lack of efficacy. In the randomized, placebo- controlled, double-blind treatment phase in which all patients were exposed to both FENTORA and placebo, data from 75 patients (95 percent of patients who reached a successful dose) were evaluable for efficacy. Key study findings include:


    -- The primary efficacy measure, the Sum of Pain Intensity Differences



       from 5 though 60 minutes (SPID60), demonstrated significantly higher



       scores compared to placebo (9.6 +/- 0.75 vs. 5.7 +/- 0.72, p<0.0001).



    -- Reduction in
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:3/26/2015)... LAKES, N.J. , March 26, 2015  Becton, ... today that it will commence offers to exchange all ... issued by CareFusion Corporation, a wholly owned subsidiary of ... described in the table below. A Registration Statement on ... of the New Notes was filed with the Securities ...
(Date:3/26/2015)... BUENA, N.J. , March 26, 2015 ... New Jersey based specialty generic pharmaceutical company, ... drug application (ANDA) to the U.S. Food and Drug ... number of ANDA submissions now pending at the FDA ... and CEO of the Company, commented, "On March 2, ...
(Date:3/26/2015)... 2015  Imagine a loved relative suffering from cancer ... the drugs are too expensive. The Austrian Centre of ... to reduce production costs of highly valued drugs significantly. ... the mercy of pathogens or cancer cells. Therapeutic antibodies ... for controlling autoimmune diseases such as multiple sclerosis. According ...
Breaking Medicine Technology:Becton, Dickinson and Company to Commence Exchange Offers 2Becton, Dickinson and Company to Commence Exchange Offers 3Becton, Dickinson and Company to Commence Exchange Offers 4Becton, Dickinson and Company to Commence Exchange Offers 5IGI Laboratories, Inc. Announces First ANDA Submission Of 2015 2World's First Method for Continuous Purification of Valuable Antibodies 2
... Alternatives International, Inc. ("NAI") (NASDAQ: NAII ), ... supplements, announced today that on February 6 it filed ... Inc. in U.S. District Court for the District of ... 8,067,381 ("the ,381 patent"), entitled "Methods and compositions for ...
... Feb. 14, 2012  Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... call and live webcast on Monday, February 27, 2011 at ... will provide a business update and review fourth quarter and ... and press release may be accessed from the Investors section ...
Cached Medicine Technology:Natural Alternatives International, Inc. Files Patent Infringement Claim Against DNP International Co., Inc. 2Natural Alternatives International, Inc. Files Patent Infringement Claim Against DNP International Co., Inc. 3
(Date:3/26/2015)... New York, NY (PRWEB) March 26, 2015 ... year to raise awareness of Parkinson’s disease and funds ... (APDA) purpose to Ease the Burden – Find the ... for registration and will take place in more than ... Phoenix, Rhode Island, New Jersey, San Antonio, Minnesota, Seattle, ...
(Date:3/26/2015)... 2015 In preparation for the 2016 ... founded by Samir Becic, has issued “report cards” ... health and fitness, as well as their promotion of ... includes Sen. Ted Cruz, who has officially announced his ... other politicians who have shown interest in running for ...
(Date:3/26/2015)... CT (PRWEB) March 26, 2015 CRN ... State Capitol Building to help celebrate the achievement of ... groundbreaking employment program serving some 500 people. , The ... The WorkPlace in partnership with the Connecticut ... and prepare long-term unemployed workers and place them at ...
(Date:3/26/2015)... Los Lunas, N.M., resident Lyndsi Alderete never ... year, when she attended a pageant and had an ... a debilitating disease of the lungs that affects the ... failure. The disease turned the Alderete’s world upside down ... pageant to raise awareness about her daughter’s disease. ...
(Date:3/26/2015)... 26, 2015 The beauty industry united ... a man who revolutionized the business of beauty education. ... Passage; founder of Pivot Point International, Inc. Passage’s wife ... of Leo. Held at the Art Institute of Chicago, ... of industry and media leaders and served as the ...
Breaking Medicine News(10 mins):Health News:American Parkinson Disease Association 2015 Optimism Walk Season Launches Nationwide 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 3Health News:CRN International Shows Support For Groundbreaking Connecticut Program To Aid The Unemployed 2Health News:Albuquerque Area Mom Enters Mrs. New Mexico Pageant to Help Fight Pulmonary Hypertension 2Health News:#BeautyChangesLives Legacy Award Pays Tribute to Industry Icon Leo Passage 2Health News:#BeautyChangesLives Legacy Award Pays Tribute to Industry Icon Leo Passage 3
... Point Action Plan on infectious waste control during a ... Monday,s Washington Times (link below), Emergency Preparedness ... issues, such as SARS, have highlighted the vulnerability our ... the area of operational sustainability in a crisis. ...
... Increase in Free Water ClearanceTOKYO and PRINCETON, N.J., ... and Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC) ... Administration (FDA) has approved SAMSCA(TM) (tolvaptan) as the ... of patients with clinically significant hypervolemic and euvolemic ...
... Experiences of Denton Regional ... DALLAS, May 21 T-System, Inc., the leading provider of ... care centers, today announced that its Emergency Department Information System ... entitled "ED Information Systems: A Guideline For Successful Implementation" in ...
... the region,s most prominent business organization, today applauded Governor ... report in Atlanta, Georgia. Greater Baltimore Committee President ... process has been of great value to the bioscience ... appreciated by the business community. He is the ...
... 17 states have won awards in the "Fight the Bite" ... Prevention and the DEET Education Program. Started in 2007, ... that encourage children and adults to protect against mosquito and ... of the winning posters are at www.fightthebitecontest.org ...
... May 21 For the second year in a row, ... donate blood through the Red Cross by joining Red ... Cross Racing is a program designed to increase the ... donate. Participants of this program can get points for a ...
Cached Medicine News:Health News:Coalition Calls on Secretary of Health to Make Hospital Emergency Preparedness a Priority 2Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 2Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 3Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 4Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 5Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 6Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 7Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 8Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 9Health News:The T SystemEV(R) Featured in Journal of Emergency Nursing Paper on Successful EDIS Implementation 2Health News:The T SystemEV(R) Featured in Journal of Emergency Nursing Paper on Successful EDIS Implementation 3Health News:'Fight the Bite' Poster Contest Honors 28 Students in 17 States 2Health News:'Fight the Bite' Poster Contest Honors 28 Students in 17 States 3Health News:NASCAR Fans Boost Blood Donations; The American Red Cross Joins 3M and Greg Biffle to Kick off Season Two 2Health News:NASCAR Fans Boost Blood Donations; The American Red Cross Joins 3M and Greg Biffle to Kick off Season Two 3
... German Craftsmanship have produced the ... world. Ocutek® now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
... of German Craftsmanship have produced ... the world. Ocutek now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
Vertical punch designed to create a 1.5mm clean cylindrical hole. Rotatable for convenient positioning. Flat Handle. Overall length 87mm....
Adjustable piston accommodates 7-9mm trephine blade. Complete punch includes base plate, piston carrier, piston for 7 - 9mm trephine blades and 18mm diameter Teflon block. Designed for accurate donor...
Medicine Products: